Madeleine Meynell
Trustee - Drug approvals NICE/SMC & Interested in drug line & restrictions
Primary HER2+ BC 2015 aged 43. Relapsed with metastatic HER2+ ER- BC in 2017. Mets in lymph nodes, liver, pleura and bones.
Progression to brain in 2019 treated with SRS. On first line Herceptin, Perjeta and Zometa.
I was born with inherited heart disease, and have an artificial heart valve and pacemaker. This is unrelated to cancer but can complicate treatment choices.
NHS patient.